Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Acute Migraine Greater than 1 year history of episodic, acute migraine (with or without aura) with onset prior to 50 years of age. Diagnosis must comply with International Headache Society (IHS) diagnostic criteria. Diagnostic must a history of at least five attacks not attributed to any other disorder that all of the following 1. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated) 2. Headache has at least two of the following characteristics: (i) unilateral location (ii) pulsating quality (iii) moderate or severe pain intensity (iv) aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) c) During headache at least one of the following: (i) nausea and/or vomiting (ii) both photophobia and phonophobia Migraine history during the 6-month period prior to the run-in period must 2-8 migraines per month and no more than 10 headache days per month Women of child-bearing potential must not be pregnant, must agree to avoid pregnancy during the trial, and must use an acceptable methods of birth control for the duration of the trial No significant ECG findings, defined by: 1. ischemic changes 2. Q-waves in at least two contiguous leads, 3. clinically significant intra-ventricular conduction abnormalities (left bundle branch block or Wolf-Parkinson-White syndrome), or 4. clinically significant arrhythmias (e.g., current atrial fibrillation) Able to understand the operation of the electronic diary and is able to apply the demo study drug patch  Contraindication to triptans Use of any prohibited concomitant medications within 10 days of the Run-in Period History of hemiplegic or basilar migraine Participation in another investigational trial during the 30 days prior to the Run-in Period or during this study Previous participation in a clinical trial of ZP-Zolmitriptan Diagnosis of cancer (other than non-invasive skin cancer) within the 5 years prior to the Run-in Period History of unstable psychiatric illness requiring medication or hospitalization in the 12 months prior to the Run-in Period Subjects who have known allergy or sensitivity to zolmitriptan or its derivatives or formulations Subjects who have known allergy or sensitivity to adhesives Planned participation in activities which cause inflammation, irritation, sunburn, lesions, or tattoos at the intended application site from two weeks prior to screening through the last day of study participation